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New frontier in glycoprotein
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Mariusz W. Szkudlinski*
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Last two decades of structure–function studies performed in numerous laboratories pro-
vided substantial progress in understanding basic science, physiological, pathophysio-
logical, pharmacological, and comparative aspects of glycoprotein hormones (GPHs) and
their cognate receptors. Multiple concepts and models developed based on experimental
data in the past stood the test of time and have been, at least in part, confirmed and/or
remained compatible with the new structures resolved at the atomic level. Major advances
in understanding of the ligand–receptor relationships are heralding the dawn of a new era
for GPHs and their receptors, although many basic questions still remain unanswered.
This article examines retrospectively several basic science aspects of GPH super-agonists
and related “biosuperiors” in a broader context of the advances in the ligand–receptor
structure–function relationships and new mechanistic models generated based on the
structure elucidation. Due to selective focus of my comments and perspectives in certain
parts, the reader is directed to the most relevant publications and reviews in the field for
more comprehensive analyses.
Keywords: glycoprotein hormone, glycoprotein hormone receptor, structure–function, protein engineering, charge
cluster, super–agonist, biosuperior, biobetter
Origins and Evolution of Function
The family of glycoprotein hormones (GPHs) consists of luteinizing hormone (LH), chorionic
gonadotropin (CG), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH),
which are heterodimers formed by the non-covalent association of a common alpha (α) and a
hormone-specific beta (β) subunit. Structurally, GPHs and their subunit ancestors belong to the
cysteine-knot growth factor superfamily and due to relatively high glycosylation are recognized
as the most complex protein hormone molecules (1–3). Their cognate GPH receptors (GPHRs)
are type A leucine-rich repeat (LRR)-containing G-protein-coupled receptors (LGR) with a large
glycoprotein extracellular domain (ECD). Early ancestors of GPHs and their receptors emerged at
the origin of metazoan animals (multicellular mitochondrial eukaryotes) (4), although two domains
of GPHRs, LRRs and 7-helix transmembrane domain (TMD), havemuch earlier evolutionary origin
and are very well-diversified in extremely large number of functionally unrelated proteins in animals
and plants (5). Parallel evolution ofGPHs, their subunits, and cognateGPHRswas previously studied
and discussed in detail (2, 6, 7). An evolution of the receptor–ligand interface likely progressed
through the series of fine-tuning within the concave face of the LRRs and activating configuration
within the hinge region located between the LRRs and TMD. Interestingly, as previously proposed
(6), numerous early vertebrate GPHRs are functioning at least in part by utilizing their constitu-
tive activity, which is determined in each individual cell by the number of receptors expressed
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in its cell membrane. Remarkably, nematode LGRs are constitu-
tively activating only the Gs/cAMP, but not Gq/IP3 inositol phos-
phate pathway (8). In addition, comparative analysis of GPHRs
signaling may suggest that Gs/cAMP pathway as the only mech-
anism of the agonist-dependent and -independent receptor acti-
vation has evolved into more diversified and complex signaling
system (9, 10).
Significant level of inherent constitutive activity is present in
various vertebrate GPHRs (11–13), including wild-type (WT)
hTSHR. In sharp contrast, human LHRs and FSHRs are activated
almost exclusively by their respective ligands and the number of
natural or artificial receptor mutations in their respective ECDs
causing constitutive activity is very low (14–16). With regard
to the TSHR, there is an apparent correlation between a high
level of basal constitutive activity and much more relaxed ligand
specificity (promiscuity), which is exemplified by the prevalence
of hCG-induced subclinical or overt hyperthyroidism in the first
trimester of pregnancy (17).
Charge Cluster in the Common α-Subunit
Significant contribution of electrostatic interactions to high
affinity receptor binding has been recognized for various lig-
and–receptor pairs, including different cysteine-knot growth fac-
tors and their respective receptors (18). Accordingly, a long-
standing postulate held that charge–charge interactions are of
major importance in the TSH–TSHR interactions (19). For the
entire G-protein-coupled receptor, strong statistical evidence was
provided that negatively charged amino acids are enriched in
the ECDs, including extracellular loops (ECLs), but positively
charged amino acids dominate within the intracellular domains
(20). Design and sequential development of human TSH and
gonadotropin super-agonists (Figure 1) were described previously
in details (1, 21, 22). Our early mutagenesis studies, which has
been recognized as “the advent of super hormone drugs” (21, 23)
focused primarily on the 11–20 region of the human α-subunit.
These studies have revealed that a basic charge cluster in this
region, which has evolved in vertebrates and disappeared in apes
and humans, is an important modulator of hormone–receptor
binding and activation. Amino acid substitutions to positively
charged lysine (K) or arginine (R) in the 11–20 region individually
(T11K/R, Q13K/R, E14K/R, P16K/R, Q20K/R) and in various
combinations increased the potency and efficacy of hTSH and
hCG (21). Such human analogs remain highly specific for their
respective receptors and inactive (up to 1000-fold higher concen-
tration) at the other GPHRs (24). The effect of these substitutions
on the in vitro bioactivity was highly correlated with their effects
on the receptor binding activity. It was repeatedly demonstrated in
media and buffers with various salt concentrations, and confirmed
by studies in other laboratories (25, 26) as well as by using CHO-
TSHRcells with largely depleted pool of the negatively charged cell
surface proteoglycans. Notably, mutations to alanine did not alter
hormone activity, indicating that only selective substitutions to K
or R amino acid residues are causing an enhancement of cAMP
and IP3 production, iodine uptake, proliferation of FRTL-5 cells,
thyroxine and progesterone production, respectively (1, 21, 24).
All our previous theoretical models of GPH–GPHR interaction
derived from super-agonist studies were placing the mutagenized
FIGURE 1 | A range of dose–response curves and relative efficacy spectrum of GPHR ligands. The efficacies of the selected classes of ligands are illustrated
by the in vitro stimulation of cAMP production and comparison with an endogenous, WT agonist (full agonist with 100% intrinsic efficacy). Although the term
“super-agonist” has not been yet officially addressed in the NC-IUPHAR nomenclature, super-agonists show higher efficacy than full agonists, variable
assay-dependent increases in receptor-binding affinity and potency, differences dependent on the receptor densities, differences related to the degree of signal
amplification in the activation cascade, and significant enhancement of clinical efficacy in human and veterinary applications. High affinity super-agonists are
especially desirable in various disorders with largely impaired receptor-binding and cell-surface expression (22, 24, 31). Multiple partial agonists of all GPHRs and
TSHR-blocking anti-TSHR antibodies (silent or orthosteric antagonists) have been studied (32), but only one human monoclonal anti-TSHR antibody was recognized
as an inverse agonist with a significant suppression of the basal constitutive activity of the WT TSHR (33).
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α-subunit αL1 and αL3 loops in a close proximity to the hinge
region and the ECLs of the receptor TMD (1, 27), very similar
to early structural predictions by Jiang et al. (28) and highly
compatible with two epitope-mapping studies (29, 30).
Super-agonists of human GPHs, also named as “superac-
tive analogs,” have been generated by introduction of positively
charged amino acid residues in selected locations of the αL1, αL3,
and βL3 beta-hairpin loops (1, 21, 27). Our “signal-enhancing
αL1 loop mutations” were described as fully consistent with the
model of receptor activation based on the structure of FSH bound
to N-terminal cysteine cluster together with the LRRs proposed
in 2005 (34). Highly unique position of the α-subunit αL1 13–20
mutations was more recently confirmed by Jiang et al. and the
structure of hFSH bound to the entire ECD of hFSHR (35)
(Figure 2). Moreover, Jiang et al. (36) discovered that such α-
subunit αL1 loop amino acid substitutions to K (21) or R (37)
are “concentrated near the top right side of the ‘activation pocket’
generating stronger electrostatic interaction to pull and lift the
sulfated-tyrosine 335 (sTyr335) of the FSHR hairpin loop,” which
is essential in the receptor activation.
GPH Super-Agonists – Tools in
Structure–Function Studies
Two step activation mechanism proposed based on
FSH–FSHR/ECD complexes (35, 36), and other structure-
based models (38, 39) incorporated and explained, at least in part,
several our previous findings as described below.
First, the new structure-based model by Jiang et al. (36) is plac-
ing much emphasis on the signal-specificity subdomain (SSSD).
It explains, at least in part, why positive charge cluster in the αL1
loop, from our studies initiated in 1995, was rescuing (restoring)
several major “loss-of-function” mutations including two muta-
tions of K51 in the α-subunit (K51A and K51P) (40), which later
have been found to be essential in the formation of salt bridge with
highly conservedD153 within the receptor LRRs domain (34) and
several others described elsewhere (1, 41) [see also Ref. (3, 38, 42,
43)]. Moreover, largely reduced binding activity and potency of
single-chain hCG and its minimized variants were restored using
αL1 loop substitutions (α4K and α4R) (25, 26). Remarkably, also
the LH activity of the hTSH/hCG “seat-belt” “determinant loop”
chimera was further increased by concomitant introduction of a
cluster of K residues (α4K) into a highly distant from “seat-belt”
αL1 13–20 domain (41). The results of several other published
and unpublished studies further reinforced the role of αL1 loop
basic charge cluster in the compensatory mechanism functioning
within the SSSD.
Second, activation of the TSHR by free or fused homodimeric
αL1 α-subunit analogs, but not the WT human α-subunits has
been detected in a concentration range only 1–2 log orders higher
than that of hTSH-WT (44, 45). Such agonistic activity of α-
subunit analogs was observed only in free, non-tethered forms,
but not in the yoked subunit-TSHR complexes constrained by the
fusion of α-subunit and TSHR. These findings first challenged the
most dominant at that time concept that the hormone-induced
receptor activation is highly restricted to interactions primarily
or exclusively within LRRs. In the light of new structures, the
FIGURE 2 | FSH–FSHR/ECD complex (PDB 4AY9) as reported by Jiang
et al. (35). The locations of human α-subunit αL1 residues 13, 14, 16, and
20 are marked by red triangles and circled in red. The α-subunit α-helix is
seen at the top as a light brown circle and is marked with a blue arrow. LRRs
together with the hinge region are forming one large domain interconnected
with three disulfide bridges. The recent “two-step model” subdivided this
domain into the hormone-binding subdomain (HBSD) and signal-specificity
subdomain (SSSD) (36).
location and configuration of “signal-enhancing substitutions”
in the activating complex is important and may not be altered,
particularly considering much weaker binding of the free α-
subunit analog than the hormone heterodimer. This explanation
is also consistent with our data indicating that synthetic linear
and cyclic peptides corresponding to the human α-subunit 11–20
residues with α4K substitutions and 10μMconcentrations are not
inducing any significant cAMP responses (45).
Third, testing hTSH-WT in comparison to hTSH super-agonist
TR1401 with the same α4K substitutions using mutated hTSHR
in the hinge region, revealed that non-conservative substitutions
E297, E303, and D382 are strongly reducing TR1401 binding
and cAMP signaling based on TSHR cell surface expression nor-
malization using FACS analysis (46). Two substitutions to the
positively charged K residue (E297K and D382K) led to partic-
ularly strong decrease of TR1401 binding and cAMP signaling.
Regardless of specific mechanism of electrostatic steering and
repulsion involved, and considering well known limitations of
simultaneous hormone and receptor mutagenesis (47–49), such
studies indicated that the analogs with a limited number of “gain-
of activity” substitutions can serve as an excellent tool for probing
hormone–receptor interactions. Use of such minimally mutag-
enized human hTSH analogs (e.g., TR1401 with α4K) together
with largely different bovine bTSH-WT (36 amino acid differ-
ence) combined with systematic receptor mutagenesis and TSHR
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expression normalization allowed to narrow interactions areas
within the hinge region and SSSD (49, 50).
Fourth, heterothyrotropic activity of mammalian GPHs can be
increased in goldfish by the same α4K substitutions and interac-
tions within the SSSD and hinge region. Such interactions likely
evolved long before diversification of LHR and TSHR receptors
(51). Co-evolution of early GPHs and their receptors, driven
by positive selection within the hormone-binding subdomain
(HBSD), related to the need for adaptation of new functions, likely
controlled “spillover” of hormone activity to other GPHRs.
Fifth, in addition to supergonists based on selective introduc-
tion of positively charged amino acid residues into the αL1 loop,
additional substitutions to R or K in the αL3 and βL3 loops led
to noticeable increases in the receptor binding both individually
and in combination (21, 52–54). The oligomerization of GPHRs
was observed in the past, but recent structures providedmore con-
vincing evidence for functional relevance of receptors oligomers,
dimers, and trimers. An interaction of βL3 loop with three muta-
tions to R (β3R) located in proximity to the FSHR trimer exosite,
suggests potential role of such exosites for additional hTSH βL3
loop binding in trimeric receptors (36, 52, 55), which could be
affected by the proportion of receptor trimers in different cells and
in vitro bioassay conditions. Although, the trimeric FSH model
does not precisely predicts the extend of cAMP increase due to
signal amplification by the adenylate cyclase, it places again the
location of both αL1 and αL3 loops near the TMD and predicts
that upon dissociation of trimers into monomers both binding
and signaling activities of glycosylated WT hFSH should increase
threefold. Dual FSHR signaling by monomers and/or by trimers
may serve as a part of evolutionarily based protection of repro-
ductive functions, and constitute a possible compensatory mech-
anism preserving some minimum level of FSH induced signaling
in various stress conditions affecting GnRH pulsatile secretion
depressing pituitary hFSH production and secretion, observed
during chronic malnutrition or starvation (56, 57). hFSHR and
likely hLHR signaling bymonomers or trimersmay alsomodulate
action of elevated endogenous gonadotropins during malignant
cell transformation in the menopausal women and their ovarian
epithelial and granulosa cells, later associated with the decreased
FSHR expression, low receptor number in the cell membrane
as well as altered receptor occupancy, trafficking, and biased
signaling (58, 59).
Although, activation of GPHRs induces the coupling of dif-
ferent G proteins (60), most of physiological activities are medi-
ated through a Gαs protein induced adenyl cyclase catalyzing
the conversion of ATP into cAMP (1). However, as suggested
by studies on TSHR deletions and others focusing on GPHRs
signaling and trafficking, “biased agonism,” also referred to as
“ligand directed signaling” is likely caused by a spectrum of dif-
ferent ligand–receptor complex conformations in combination
with other cell-specific factors (1, 61–63). Recent studies indi-
cated that different GPH glycoforms may have distinct effects
on signaling and result in a biased agonism (64). Thus, it is
expected that each GPH variant may have different and some-
times completely unique signaling pattern. However, there is
also pharmacologically justified possibility that super-agonists
are in general less capable of inducing multiple conformations
and therefore much less biased (65). Selected super-agonists
are known to have an extended receptor-residence time, which
in turn may affect GPHR interactions with the cell adapter
proteins, endosome signaling, and signal compartmentalization
(61, 66–68).
In summary, new investigative strategies including “charge
scanning and reversal mutagenesis,” “loss-of-function restora-
tion by superagonist,” as well as “loss-of-superagonism” with
mutated or truncated GPHRs constitute highly valuable tools in
the structure-function studies both in the absence and presence
of structural information (1, 46, 53, 69). We have first showed
directly using large deletions that the ECD suppresses an inher-
ent constitutive activity of the TMD of the human TSHR (14).
Such an intrinsic property of the ECD acting on the TMD as a
partial inverse agonist was recognized after introduction of the
“driver hemagglutinin (HA) tag-sequence” at the N-terminus of
the truncated constructs designed to improve and assess cell sur-
face expression (14). We have demonstrated that the presence of
such “driver sequence” in the TSHR and other GPHRs constructs
with large ECD deletions in the ECD is absolutely necessary for
an efficient cell surface expression (1, 14, 70). Similar “driver
sequences” were subsequently used to express and normalize
expression of various other GPHR constructs with several major
ECD deletions, assess their interactions with analogs, and deter-
mine their constitutive activities in both cAMP and IP3 signaling
pathways (1, 15, 62). Several newer studies analyzing the role
of charged residues in the receptor hinge region attributed an
inherent agonistic property to this domain and supported our
early concept that the receptor charge clusters adjacent to the
TMD are critical in a downstream signal transmission (49, 50, 71).
Development of GPH Biosuperiors and
Other Related Molecules
“Biosuperiors” (biobetters or next-generation biological therapeu-
tics) are defined as the second-generation products with substan-
tial advantages over the originator molecules. Biosuperiors have
the same receptor target and general mechanism of action as pre-
viously approved WT recombinant molecules but include struc-
tural changes and/or altered properties that result in an improve-
ment in their clinical profile. GPH biosuperiors can be classified
into three main categories: super-agonists, long-acting analogs,
and WT molecules with optimized glycosylation, formulation, or
delivery.
Long-acting bovine FSH super-agonists with much higher effi-
cacy than all other products in veterinary markets have been
developed at Trophogen Inc. and entered clinical trials for super-
ovulation in cows and heifers (72). Human TSH and FSH super-
agonists for diagnostic and therapeutic applications in the thy-
roid cancer of follicular origin and the treatment of infertility,
including poor responders in the controlled ovarian stimula-
tion (COS), respectively, have entered the late-phases of preclin-
ical development (22, 24, 37, 73). Long-acting analog of WT
hFSH (corifollitropin alfa; ElonvaR, Merck) has been approved
in Europe for COS. It was constructed by fusion of the carboxy-
terminal peptide of the β-subunit of hCG to the β-subunit of
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hFSH. Such additional 28 amino acid residues peptide containing
4-5 O-linked carbohydrate chains resulted in twofold increase
in the FSH plasma half-life. Elonva® substituted for 7 days daily
injection of the WT hormone in the standard COS procedure
(74–76). Additional post-approval assessments are expected to
determine its clinical convenience value and acceptance in the IVF
market. Glyco-optimized highly sialylatedWT FSH (FSH-GEX™)
developed by Glycotope GmbH is based on its production in the
human GT-5s cell line providing more optimal glycan structure
pattern than standard CHO cell line (77). Similar efforts are now
also directed to engineering CHO cells and generation of more
homogenous FSH glycosylation, including “human-like” α2,6-
terminal sialic acid linkages (78). Recent developments of vari-
ous GPH biosimilars, improved formulations (79), injection fre-
quency and convenience-focused preparations have not addressed
several largely unmet needs formuch higher efficacy-based biosu-
periors (80, 81).
Clinical utility of thyrostimulin, GPH-related protein found in
both vertebrates and invertebrates (82), still awaits full elucidation
and rigorous assessment of specificity, selectivity and potential, if
any, therapeutic benefits. Small molecules given orally may also
lack sufficient specificity, but modified and/or minimized protein
variants may provide sufficient balance between specificity, selec-
tivity, half-life and convenience of enteral or topical administra-
tion (83). In contrast to large GPHs, there is largely incorrect per-
ception that highly improved affinity of smallmolecules toGPHRs
should result in parallel increase of their specificity. However, the
specificity of small molecules ismore relative to the degree of non-
relevant binding than the strength of their interactionwith specific
receptor (84). These reservations aside, during the last 10 years,
several new advances have been made in the development of
GPHR small molecule ligands and allosteric modulators (85–87).
Closing Remarks and Future Perspectives
Glycoprotein hormone–glycoprotein hormone receptor struc-
ture–function research is evolving into new highly promising
phase, which will likely culminate in elucidation of the entire
active and inactive structure(s) of hormone–receptor complexes,
including constitutively active receptors, entire receptors bound to
super-agonists, antibodies and smallmolecule ligands. The advent
of new optical techniques based on FRET and BRET sensors,
as well as single-molecule microscopy, will allow more detailed
analysis of real-time receptor activation and direct spatial assess-
ment of signaling in the living cells. Such new optical techniques
made already possible detection of TSHR signaling to cAMP after
receptor internalization into endosomes (68, 88).
In analogy to human genome sequencing, full benefits of the
structure–function achievements may not immediately translate
into the new drugs and the third generation of GPH biosuperiors
and theranostics. Further progress in the understanding of func-
tional and therapeutic potential of signaling bias, receptor trimer-
ization, trafficking, compartmentalization of signaling as well as
detailed elucidation of the mechanism of super-agonists binding
and signaling, should move this field to a new very exciting times
of personalized drugs with predefined pharmacodynamics (PD),
pharmacokinetics (PK), and signaling profiles (89).
Future third-generation recombinant protein biosuperiors will
likely have even more advantages related to efficacy, potency and
half-life, but also in relation to largely improved stability, formu-
lation, bioavailability, and new methods of administration, elimi-
nating the need for multiple injections (83, 90). New automated
single-use sensor-based manufacturing technology platforms of
biologics as well as largely improved purification and characteri-
zation methods should make a whole development process faster,
safer, and more efficient, assuming necessary improvement and
streamlining in the regulatory agencies, their flexibility, commit-
ment to a case-by-case considerations and willingness to accept
well justified unorthodox development strategies.
It is apparent to many biotechnology experts and market ana-
lysts that major biosuperiors, which are largely improved versions
of the originator molecules, will be the next big opportunity in
the entire field of biologics and GPCR protein ligands (80). It is
predicted that biotech and pharma companies, well known for
innovation and experience with the first-generation recombinant
proteins and biosimilars, will be the best positioned to achieve
early success with biosuperiors as well as with the biosuperior-
based targeting conjugates and the nanoparticles with theranostic
capabilities. New highly exciting frontier of precision medicine
combining targeted and personalized interventions is already
looming on the horizon. The sense of wonder, excitement, and
anticipation of the future progress in the structure–function and
novel drug design can be well expressed by Carl Sagan’s visionary
quote: “Somewhere, something incredible is waiting to be known.”
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